Key Details
Price
$0.82Annual ROE
-168.50%Beta
1.85Events Calendar
Next earnings date:
May 02, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Mar 02, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 21, 2015Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon's chief executive officer and director, will present at two upcoming investor conferences in December.
Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions
Start Time: 17:00 January 1, 0000 5:55 PM ET Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q3 2024 Earnings Call November 12, 2024, 17:00 PM ET Company Participants Mike Exton - CEO and Director Tom Garner - SVP and Chief Commercial Officer Craig Granowitz - SVP and Chief Medical Officer Alan Main - EVP, Innovation and Chemical Sciences Lisa DeFrancesco - Head, IR and Corporate Strategy Conference Call Participants Andrew Tsai - Jeffries Joseph Stringer - Needham and Company Joe Pantginis - H.C. Wainwright Yigal Nochomovitz - Citigroup Roanna Ruiz - Leerink Partners Operator Good day, and welcome to the Lexicon Pharmaceuticals Third Quarter 2024 Results Conference Call.
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe
THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin), an oral SGLT1/SGLT2 inhibitor, as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). The Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, as defined in the voting question as having estimated glomerular filtration rate (eGFR) > 45 to 60 mL/min/1.73 m2 and urine albumin-to-creatinine ratio (uACR) > 30mg/g.
Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease.
THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing.
Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin
The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.
FAQ
- What is the primary business of Lexicon Pharmaceuticals?
- What is the ticker symbol for Lexicon Pharmaceuticals?
- Does Lexicon Pharmaceuticals pay dividends?
- What sector is Lexicon Pharmaceuticals in?
- What industry is Lexicon Pharmaceuticals in?
- What country is Lexicon Pharmaceuticals based in?
- When did Lexicon Pharmaceuticals go public?
- Is Lexicon Pharmaceuticals in the S&P 500?
- Is Lexicon Pharmaceuticals in the NASDAQ 100?
- Is Lexicon Pharmaceuticals in the Dow Jones?
- When was Lexicon Pharmaceuticals's last earnings report?
- When does Lexicon Pharmaceuticals report earnings?
- Should I buy Lexicon Pharmaceuticals stock now?